TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the ...

In EARLY TAVR, intervention improved outcomes over waiting in patients with class II or no indications for AVR consideration.

The findings highlight the importance of having an EP versed in lead management on the heart valve team, one expert says.

The procedures are not mutually exclusive, however, and should be considered on a patient-by-patient basis, a researcher says ...

In an early look at SCOT-HEART 2, CCTA led more primary-prevention patients to make changes to reduce their risk of CVD.

Labels for the Pfizer and Moderna shots, which already caution about myocarditis and pericarditis, will more strongly stress ...

This month: pharmacy’s growing CICU role, arrhythmias’ impact on pregnancy, Life’s Essential 8 in practice, and more.

PanEcho isn’t yet ready to be a standalone tool, researchers say, but shows promise at improving workflows and patient care.

In DETECT AS, the passive notifications improved rates of AVR and boosted survival, with bigger gains in women.

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.

Acute MI mortality has fallen, yet deaths from other diseases, including heart failure and hypertension, are on the rise.